相关实验视频
Updated: Jun 16, 2025

04:44
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
225
多巴胺D3受体基因与强迫症和抗抑郁药物反应有关
Gwyneth Zai1, Clement C Zai1, Eliza Burroughs2
1Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry and Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
概括
多巴胺D3受体 (DRD3) 基因中的遗传变异与强迫症 (OCD) 和发病时的年龄有关. 特定的DRD3多态性也显示了强迫症患者对治疗反应的联系.
科学领域:
- 神经遗传学 神经遗传学
- 精神疾病 精神疾病
背景情况:
- 强迫症 (OCD) 是一种常见的神经精神疾病,具有重要的遗传基础.
- 虽然多巴胺受体基因与强迫症有关,但多巴胺D3受体 (DRD3) 基因的探索较少.
- 神经生物学证据表明DRD3在与强迫行为和焦虑相关的条状皮质电路中的作用.
研究的目的:
- 研究多巴胺D3受体 (DRD3) 基因的遗传变异与强迫症 (OCD) 之间的关联.
- 探索DRD3多态化与强迫症患者对血红素再吸收抑制剂 (SRI) 治疗的反应之间的关系.
- 分析DRD3变异与临床特征的关联,例如发病年龄 (AAO) 和症状严重程度 (耶鲁-布朗强迫症-强迫症量表-Y-BOCS).
主要方法:
- 在318名强迫症患者和196名健康对照中检查了DRD3基因的9种多态.
- 用于核家庭的基于家庭的关联测试 (FBAT) 和独立病例的病例控制分析.
- 进行了量化分析,将多态度与发病时的年龄 (AAO) 和耶鲁-布朗强迫症度表 (Y-BOCS) 分数相关联.
主要成果:
- FBAT发现了几个DRD3多态 (rs2399504,rs7611535,rs1394016,Ser9Gly,rs167770,rs2087017) 的名义上显著的偏差传播.
- 多态体rs2399504,rs7611535,rs1394016,Ser9Gly和rs167770与发病时的年龄 (AAO) 有关,但与Y-BOCS得分无关.
- 哈普洛型分析确定了与强迫症相关的特定标志物组合. 在多次测试校正后,发现rs167770,rs11721264和塞特拉林反应之间存在显著的关联.
结论:
- 这项研究为多巴胺D3受体 (DRD3) 基因在强迫症 (OCD) 中的参与提供了新的证据.
- 特定的DRD3多态性与强迫症患者的发病年龄有关.
- 这些发现表明DRD3在强迫症病原和治疗反应中的潜在作用,需要进一步调查.
相关概念视频
Human Genetics
549
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
549
Obsessive-Compulsive Disorder
71
Obsessive-compulsive disorder (OCD) is a mental health condition characterized by recurrent obsessions, compulsions, or both, which consume significant time and interfere with daily functioning. Obsessions involve persistent, intrusive, and unwanted thoughts, images, or urges that evoke anxiety. Common examples include irrational fears of contamination or harm. Compulsions are repetitive behaviors or mental acts performed to reduce the anxiety caused by obsessions. For instance, individuals...
71
Antidepressant Drugs: MAOIs and Other Agents
205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205
G-protein Coupled Receptors
117.2K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
117.2K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K

